Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 28

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Ischaemic stroke

Recruiting

Study on the Effects of Mepivacaine Hydrochloride for Patients with Neurological Symptoms After Ischemic Stroke

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mepivacaine Hydrochloride
  • Sponsor:Assistance Publique Hopitaux De Paris

Infant sedation

Recruiting

Study on Sedation Effects of Dexmedetomidine vs. Midazolam in Mechanically Ventilated Preterm Infants

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Midazolam
  • Sponsor:Assistance Publique Hopitaux De Paris

Glioblastoma multiforme

Recruiting

Long-term safety study of Temferon (modified stem cells with interferon-α2) in patients previously treated for glioblastoma multiforme

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Cd34+ Haematopoietic Stem And Progenitor Cells Transduced With A Lentiviral Vector Encoding The Interferon Alpha-2 Gene
  • Sponsor:Genenta Science S.p.A.

Neurofibromatosis

Recruiting

Study on Crizotinib for Treating Severe Neurofibromatosis Type 2 in Children Not Eligible for Surgery or Radiotherapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Crizotinib
  • Sponsor:Medical University Of Warsaw

Multiple sclerosis

Recruiting

Study on Stopping Dimethyl Fumarate and Drug Combination in Patients Aged 55+ with Inactive Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dimethyl Fumarate
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Craniocerebral injury

Recruiting

Study on the Effects of Cerebrolysin and Sodium Chloride for Recovery in Patients with Moderate to Severe Traumatic Brain Injury

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Foundation For The Study Of Nanoneuroscience And Neuroregeneration

Angelman's syndrome

Recruiting

Study on the Safety and Effects of ION582 for Patients with Angelman Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:2'-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Ube3A Antisense Transcript Rna
  • Sponsor:Ionis Pharmaceuticals Inc.

Parkinson's disease

Recruiting

Study on Amantadine for Reducing Motor Fluctuations in Advanced Parkinson's Disease Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amantadine Hydrochloride
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Atrial fibrillation+2

Recruiting

Study on Aspirin and Clopidogrel for Patients with Atrial Fibrillation After Left Atrial Appendage Closure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clopidogrel
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Seizure

Recruiting

Study on the Safety and Effectiveness of Alprazolam for Treating Long Seizures in Patients Aged 12 and Older

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alprazolam
  • Sponsor:UCB Biopharma

Myotonic dystrophy

Recruiting

Study on the Effects of Mexiletine for Treating Myotonic Dystrophy Types 1 and 2 in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings SA

Sedative therapy+1

Recruiting

A Study Comparing Remimazolam and Midazolam for Sedation in Adults During Upper Gastrointestinal Endoscopy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Midazolam
  • Sponsor:Sint Antonius Ziekenhuis Stichting

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.